System for delivering therapeutic agents into living cells and cells nuclei

1. An oligomeric compound having the general Formula I:

wherein:

n is an integer from 3 to 20;

each of X 1 -Xn is independently a residue of a building block of the oligomer, wherein said residue or building block is represented by the general structure: -J-O—P(═O)(Ra)—O—;

wherein:

J is alkyl, cycloalkyl, aryl, ether, amide or carboxy;

Ra is hydrogen, hydroxyl, alkoxy, aryloxy, alkyl, phenyl, aryl, cycloalkyl, thiohydroxy, thioalkoxy or thiaryloxy;

each of L 1 -Ln is independently a first linking group or absent, wherein said first linking group is methylene, substituted or unsubstituted saturated or unsaturated C 4 -C 10 hydrocarbon chain, or substituted or unsubstituted saturated or unsaturated C 4 -C 10 hydrocarbon chain interrupted by at least one heteroatom selected from oxygen, nitrogen and sulfur;

each of A 1 -An is independently a second linking group attached to J or absent, wherein said second linking group is methylene, substituted or unsubstituted saturated or unsaturated C 2 -C 10 hydrocarbon chain, or substituted or unsubstituted saturated or unsaturated C 2 -C 10 hydrocarbon chain interrupted by at least one heteroatom selected from oxygen, nitrogen and sulfur;

each of Y 1 -Yn is independently a delivering group, wherein said delivering group is amine; guanidine, histidine or imidazole;

each of B 1 and B 2 is independently a spacer or absent, wherein said spacer is allylamine, diaminoethane, diaminohexane, substituted or unsubstituted saturated or unsaturated C 2 -C 10 hydrocarbon chain, or substituted or unsubstituted saturated or unsaturated C 2 -C 10 hydrocarbon chain interrupted by at least one heteroatom selected from oxygen, nitrogen and sulfur; and

each of Z 1 and Z 2 is independently a reactive group capable of binding a biologically active moiety or hydrogen, provided that at least one of Z 1 and Z 2 is amine, halide, hydroxy, amide, amide, carboxy, thiol, thioamide, thiocarboxy, alkoxy, thioalkoxy, aryloxy, thioaryloxy, hydrazine, hydrazide, phosphoramidite, phosphate, phosphonate, phosphine or any combination thereof; and

wherein Z 1 , Z 2 and/or Y 1 -Y n can each independently be protected by an amine protecting group selected from formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (“CBZ”), tert-butoxycarbonyl (“Boc”), trimethylsilyl (“TMS”), 2-trimethylsilylethanesulfonyl (“SES”), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (“FMOC”), nitro-veratryloxycarbonyl (“NVOC”); hydroxy protecting groups selected from benzyl, and trityl ethers as well as alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers, allyl ethers, monomethoxytrityl and dimethoxytrityl.

2. The compound of claim 1 , wherein n is an integer from 6 to 12.

3. The compound of claim 1 , wherein each of said first linking moieties is methylene (CH 2 ).

4. The compound of claim 1 , comprising at least four delivering groups.

5. The compound of claim 1 , wherein said biologically active moiety is selected from the group consisting of a therapeutically active agent, a labeling moiety, or any combination thereof.

6. A conjugate comprising at least one delivery moiety and at least one biologically active moiety being linked thereto, said delivery moiety being an oligomeric compound having the general Formula II:

wherein:

n is an integer from 4 to 20;

each of X 1 -Xn is independently a residue of a building block of said oligomer, wherein said residue or building block is represented by the general structure: -J-O—P(═O)(Ra)—O—;

wherein:

J is alkyl, cycloalkyl, aryl, ether, amide or carboxy;

Ra is hydrogen, hydroxyl, alkoxy, aryloxy, alkyl, phenyl, aryl, cycloalkyl, thiohydroxy, thioalkoxy or thiaryloxy;

each of L 1 -Ln is independently a first linking group or absent, wherein said first linking group is methylene, substituted or unsubstituted saturated or unsaturated C 4 -C 10 hydrocarbon chain, or substituted or unsubstituted saturated or unsaturated C 4 -C 10 hydrocarbon chain interrupted by at least one heteroatom selected from oxygen, nitrogen and sulfur;

each of A 1 -An is independently a second linking group attached to J or absent, wherein said second linking group is methylene, substituted or unsubstituted saturated or unsaturated C 2 -C 10 hydrocarbon chain, or substituted or unsubstituted saturated or unsaturated C 2 -C 10 hydrocarbon chain interrupted by at least one heteroatom selected from oxygen, nitrogen and sulfur;

each of Y 1 -Yn is independently a delivering group, wherein said delivering group is amine; guanidine, histidine or imidazole;

each of B 1 and B 2 is independently a spacer or absent, wherein said spacer is allylamine, diaminoethane, diaminohexane, substituted or unsubstituted saturated or unsaturated C 2 -C 10 hydrocarbon chain, or substituted or unsubstituted saturated or unsaturated C 2 -C 10 hydrocarbon chain interrupted by at least one heteroatom selected from oxygen, nitrogen and sulfur; and

each of T 1 and T 2 is independently a binding group binding said biologically active moiety or absent, wherein said binding group is a covalent bond selected from: amide bond, ester bond, ether bond, thioether bond, phosphate bond, or phosphodiester bond;

wherein at least one of said T 1 and T 2 is said binding group; and

wherein said biologically active moiety is selected from: oligonucleotide, labeling moiety, and oligonucleotide attached to a labeling moiety.

7. The conjugate of claim 6 , comprising at least one delivery moiety and at least two biologically active moieties being linked thereto via said binding groups.

8. The conjugate of claim 6 , comprising at least two delivery moieties and at least two biologically active moieties being linked thereto via said binding groups.

9. The conjugate of claim 8 , wherein each of said at least two biologically active moieties is attached to each of said at least two delivery moieties.

10. The conjugate of claim 8 , wherein at least one of said at least two biologically active moieties is an oligonucleotide.

11. The conjugate of claim 10 , wherein at least one of said at least two biologically active moieties is a second oligonucleotide being capable of hybridizing said oligonucleotide.

12. The conjugate of claim 11 , wherein said second oligonucleotide is hybridized to said oligonucleotide.

13. The conjugate of claim 6 , wherein at least one of said at least biologically active moieties comprises a labeling moiety.

14. A method of delivering a biologically active moiety to a cell, the method comprising:

contacting said cell with the conjugate of claim 6 , thereby delivering the biologically active moiety to the cell.

15. A pharmaceutical composition comprising the conjugate of claim 6 and a pharmaceutically acceptable carrier.

16. The pharmaceutical composition of claim 15 , being packaged in a packaging material and identified in print, in or on said packaging material, for use in the treatment and/or diagnosis of a condition in which delivering said biologically active moiety to a cell is beneficial.

17. A process of preparing the conjugate of claim 6 , the process comprising:

providing at least one oligomeric compound having the general Formula III:

wherein:

n is an integer from 4 to 20;

each of X 1 -Xn is independently a residue of a building block of the oligomer, wherein said residue or building block is represented by the general structure: -J-O—P(═O)(Ra)—O—;

wherein:

J is alkyl, cycloalkyl, aryl, ether, amide or carboxy;

Ra is hydrogen, hydroxyl, alkoxy, aryloxy, alkyl, phenyl, aryl, cycloalkyl, thiohydroxy, thioalkoxy or thiaryloxy;

each of L 1 -Ln is independently a first linking group or absent, wherein said first linking group is methylene, substituted or unsubstituted saturated or unsaturated C 4 -C 10 hydrocarbon chain, or substituted or unsubstituted saturated or unsaturated C 4 -C 10 hydrocarbon chain interrupted by at least one heteroatom selected from oxygen, nitrogen and sulfur;

each of A 1 -An is independently a second linking group attached to J or absent, wherein said second linking group is methylene, substituted or unsubstituted saturated or unsaturated C 2 -C 10 hydrocarbon chain, or substituted or unsubstituted saturated or unsaturated C 2 -C 10 hydrocarbon chain interrupted by at least one heteroatom selected from oxygen, nitrogen and sulfur;

each of V 1 -Vn is independently a delivering group or a group capable of being converted to a delivering group, wherein said delivering group is amine, guanidine, histidine or imidazole;

each of B 1 and B 2 is independently a spacer or absent, wherein said spacer is allylamine, diaminoethane, diaminohexane, substituted or unsubstituted saturated or unsaturated C 2 -C 10 hydrocarbon chain, or substituted or unsubstituted saturated or unsaturated C 2 -C 10 hydrocarbon chain interrupted by at least one heteroatom selected from oxygen, nitrogen and sulfur; and

each of Z 1 and Z 2 is independently a reactive group capable of binding said biologically active moiety, or hydrogen, provided that at least one of Z 1 and Z 2 is amine, halide, hydroxy, amide, amide, carboxy, thiol, thioamide, thiocarboxy, alkoxy, thioalkoxy, aryloxy, thioaryloxy, hydrazine, hydrazide, phosphoramidite, phosphate, phosphonate, phosphine or any combination thereof;

providing at least one biologically active compound having at least one functional group capable of reacting with said reactive group; and

coupling said at least one biologically active compound and said compound having said Formula III, thereby obtaining the conjugate.

18. The process of claim 17 , wherein said coupling is effected by reacting at least one of said reactive groups and at least one of said functional groups.

19. The process of claim 17 , wherein at least one of said V 1 -Vn is a group capable of being converted to said delivering group, the process further comprising, prior to, during or subsequent to said coupling:

converting said group to a delivering group.

20. The process of claim 17 , wherein at least one of said biologically active moiety and said oligomeric compound is attached to a solid support.

21. The process of claim 20 , further comprising, subsequent to said coupling, detaching the conjugate from said solid support.

22. The process of claim 17 , wherein providing said oligomeric compound having said general formula III comprises:

providing an oligomeric compound having a plurality of said building blocks linked therebetween; and

attaching at least one delivering group and/or a group capable of being converted to said delivering group to at least one of said building blocks.

23. The process of claim 17 , wherein providing said oligomeric compound having said general formula III comprises:

providing a plurality of compounds each independently having the general formula IV:

wherein:

X is a residue of a building block of the oligomer, wherein said residue or building block is represented by the general structure: -J-O—P(═O)(Ra)—O—; wherein:

J is alkyl, cycloalkyl, aryl, ether, amide or carboxy;

Ra is hydrogen, hydroxyl, alkoxy, aryloxy, alkyl, phenyl, aryl, cycloalkyl, thiohydroxy, thioalkoxy or thiaryloxy;

A is a linking group attached to J or absent, wherein said linking group is methylene, substituted or unsubstituted saturated or unsaturated C 2 -C 10 hydrocarbon chain, or substituted or unsubstituted saturated or unsaturated C 2 -C 10 hydrocarbon chain interrupted by at least one heteroatom selected from oxygen, nitrogen and sulfur;

V is a delivering group, or a group capable of being converted to said delivering group, wherein said delivering group is amine, guanidine, histidine or imidazole;

each of G 1 and G 2 is independently a linking group or absent;

K 1 is a first reactive group; and

K 2 is a second reactive being capable of reacting with said first reactive group, provided that in at least one of said compounds having said general Formula III Vn is said delivering group or said group capable of being converted to said delivering group; and

reacting said first reactive group and said second reactive group, thereby obtaining said oligomeric compound.

24. The process of claim 23 , wherein said residue of said building block and said first reactive group form together a phosphoramidite residue.

25. The compound of claim 1 , wherein said compound is represented by the following structure:

wherein each of m and n is independently an integer ranging from 0-20, and n and m cannot be both 0.

26. The conjugate according to claim 6 , said conjugate is represented by the following structure:

wherein each of m and n is independently an integer ranging from 0-20, and n and m cannot be both 0.